Summit Therapeutics Publishes Scientific Updates to Corporate Website
May 06, 2021 08:00 ET
|
Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our...
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
May 05, 2021 12:47 ET
|
Summit Therapeutics Inc.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight...
Summit Therapeutics Announces Commencement of Rights Offering
April 21, 2021 08:04 ET
|
Summit Therapeutics Inc.
Summit Therapeutics Inc.(‘Summit’ or the ‘Company’) Summit Therapeutics Announces Commencement of Rights Offering Cambridge, MA, April 21, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today...
Summit Therapeutics Announces Rights Offering
March 26, 2021 07:00 ET
|
Summit Therapeutics Inc.
Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the...
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020
November 12, 2020 12:30 ET
|
Deinove
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020 ·Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the...
Summit Announces Results of Court Meeting and General Meeting
August 19, 2020 16:01 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Results of Court Meeting and General Meeting Oxford, UK, and Cambridge, MA, US, August 19, 2020 – Summit Therapeutics plc...
Summit Announces Intention to Redomicile its Holding Company to the United States
July 16, 2020 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Intention to Redomicile its Holding Company to the United States Oxford, UK, and Cambridge, MA, US, July 16, 2020 –...
Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
July 13, 2020 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge, MA, US, July 13, 2020...
Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress
April 30, 2020 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational...
Summit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDI
December 21, 2017 02:00 ET
|
Summit Therapeutics plc
Summit to receive $2.5 million upfront paymentUp to $25 million in development, regulatory, pricing and initial sales milestonesSummit retains commercial rights to ridinilazole in rest of the world ...